Mersana Therapeutics, Inc. - Special Call Transcript
Good morning, and welcome to Mersana Therapeutics Immunosynthen STING-Agonist ADC Platform Webinar. (Operator Instructions)
I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Good morning. Welcome to Mersana's webinar highlighting our Immunosynthen STING-Agonist ADC platform and pipeline. A replay of today's webinar will be available on the Investors & Media section of our website. After our prepared remarks, we will open the call for Q&A.
Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of company's plans to vary
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |